Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Pollak

Showing results (161-170 of 237) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06cFred Saad, Sebastien Hotte, Scott North, et al.
Obesity (Silver Spring, Md.)|May 14, 2013
Serum leptin and adiponectin levels and risk of renal cell carcinomaLinda M Liao, Kendra Schwartz, Michael Pollak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2008
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myelomaMartha Q Lacy, Melissa Alsina, Rafael Fonseca, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2010
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progressionLuc Furic, Liwei Rong, Ola Larsson, et al.
European Urology|January 14, 2014
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09)Christian Rothermundt, Stefanie Hayoz, Arnoud J Templeton, et al.
The Journal of Biological Chemistry|June 16, 2018
Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradationCristina E Tognon, Bo Rafn, Naniye Malli Cetinbas, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 9, 2005
Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancerJeffrey A Meyerhardt, Jeffrey A Sloan, Daniel J Sargent, et al.
Oncotarget|September 9, 2017
Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cellsMamatha Bhat, Akiko Yanagiya, Tyson Graber, et al.
Oncotarget|October 20, 2023
Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancerDevalingam Mahalingam, Salih Hanni, Anthony V Serritella, et al.
Oncotarget|June 19, 2023
Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancerDevalingam Mahalingam, Salih Hanni, Anthony V Serritella, et al.
Pageof 24

Showing results (161-170 of 237) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06cFred Saad, Sebastien Hotte, Scott North, et al.
Obesity (Silver Spring, Md.)|May 14, 2013
Serum leptin and adiponectin levels and risk of renal cell carcinomaLinda M Liao, Kendra Schwartz, Michael Pollak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2008
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myelomaMartha Q Lacy, Melissa Alsina, Rafael Fonseca, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2010
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progressionLuc Furic, Liwei Rong, Ola Larsson, et al.
European Urology|January 14, 2014
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09)Christian Rothermundt, Stefanie Hayoz, Arnoud J Templeton, et al.
The Journal of Biological Chemistry|June 16, 2018
Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradationCristina E Tognon, Bo Rafn, Naniye Malli Cetinbas, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 9, 2005
Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancerJeffrey A Meyerhardt, Jeffrey A Sloan, Daniel J Sargent, et al.
Oncotarget|September 9, 2017
Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cellsMamatha Bhat, Akiko Yanagiya, Tyson Graber, et al.
Oncotarget|October 20, 2023
Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancerDevalingam Mahalingam, Salih Hanni, Anthony V Serritella, et al.
Oncotarget|June 19, 2023
Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancerDevalingam Mahalingam, Salih Hanni, Anthony V Serritella, et al.
Pageof 24